U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07950267) titled 'Real-world Evidence of Inebilizumab in IgG4-RD' on Nov. 08.

Brief Summary: The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.

This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.

Study Start Date: Jan., 2027

Study Type: OBSERVATIONAL

Condition: IgG4-Related Di...